Design, synthesis, and anticancer activity of novel isocryptolepine ‘aza’ type acyl thiourea derivatives via combined experimental and computational approach


Fayyaz A., Ejaz S. A., Ahmed A., Channar P. A., Afzal S., Ujan R., ...More

Bioscience Reports, vol.46, no.1, pp.1-31, 2026 (SCI-Expanded, Scopus) identifier identifier

  • Publication Type: Article / Article
  • Volume: 46 Issue: 1
  • Publication Date: 2026
  • Doi Number: 10.1042/bsr20253519
  • Journal Name: Bioscience Reports
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, EMBASE, MEDLINE
  • Page Numbers: pp.1-31
  • Hacettepe University Affiliated: Yes

Abstract

To identify novel tyrosinase inhibitors, a series of isocryptolepine ‘aza’ type acyl thiourea analogs (6a–6h) were designed and synthesized using a multistep strategy. Spectroscopic methods including FTIR, UV–vis, 1H NMR, 13C NMR, and EI-MS were utilized for detailed analysis of compounds. Their tyrosinase inhibitory activities were evaluated in vitro, demonstrating superior potency compared with kojic acid (IC50 = 16.83 ± 1.162 μM). The synthesized compounds exhibited IC50 values ranging from 0.832 ± 0.03 to 7.945 ± 0.63 μM, with compound 6g emerging as the most potent inhibitor (IC50 = 0.832 ± 0.03 μM). Kinetic studies revealed competitive inhibition by compound 6g, highlighting its potential as a lead candidate for treating tyrosinase-mediated hyperpigmentation. Additional evaluations showed that these compounds also effectively inhibited other enzymes involved in cancer progression, indicating their broad therapeutic potential. Molecular modeling studies against the tyrosinase enzyme (PDB: 4OUA) confirmed strong binding interactions, while structure-activity relationship analyses provided insights into their inhibitory mechanisms. Geometry optimization of the compounds, supporting their favorable molecular properties. Drug-likeness evaluations further validated the potential of these analogs as promising anti-tyrosinase agents. Overall, this study establishes compound 6g and its analogs as compelling candidates for further development in hyperpigmentation and cancer therapeutics.